Franz P. Rischard

Franz P. Rischard

Auto-generated profile, based on publicly available information

Franz P. Rischard

University of Arizona

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
SNSteven D. Nathan
Steven D. Nathan
VTVictor F. Tapson
Victor F. Tapson
JEJean Marie Elwing
Jean Marie Elwing
FRFranz Rischard
Franz Rischard
JMJinesh Mehta
Jinesh Mehta
AWAaron B. Waxman
Aaron B. Waxman
Rationale: The INCREASE study of inhaled treprostinil met its primary endpoint of change in 6-minute-walk distance at Week 16. In addition, there were significantly fewer clinical worsening events in patients receiving inhaled treprostinil. However, the incidence of multiple events in the same patient is unknown. Objectives: This post hoc analysis evaluated the effect of continued treatment with inhaled treprostinil on the frequency and impact of multiple disease progression events. Methods: Patients enrolled in INCREASE were analyzed for disease progression events, defined as at least 15% decline in 6-minute-walk distance, exacerbation of underlying lung disease, cardiopulmonary hospitalization, lung transplantation, at least 10% decline in forced vital capacity, or death during the duration of the 16-week study. Measurements and Main Results: In total, 147 disease progression events occurred in the inhaled treprostinil group (89/163 patients, 55%) compared with 215 events (109/163 patients, 67%) in the placebo group (P = 0.018). There was a lower incidence of each disease progression component in the inhaled treprostinil group: 6-minute-walk distance decline (45 vs. 64 events), lung disease exacerbation (48 vs. 72 events), FVC decline (19 vs. 33), cardiopulmonary hospitalization (23 vs. 33 events), and death (10 vs. 12). Fewer patients receiving inhaled treprostinil had multiple progression events compared with those receiving the placebo (35 vs. 58, 22% vs. 36%; P = 0.005). Conclusions: Patients who received inhaled treprostinil were significantly less likely to experience further disease progression events after an initial event compared with patients receiving placebo. These results support the continuation of inhaled treprostinil despite the occurrence of disease progression in clinical practice.

1 May 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
AWAaron B. Waxman
Aaron B. Waxman
DSDavid M. Systrom
David M. Systrom
SMSolaiappan Manimaran
Solaiappan Manimaran
JPJanethe de Oliveira Pena
Janethe de Oliveira Pena
JLJonathan Lu
Jonathan Lu
FRFranz P. Rischard
Franz P. Rischard
BACKGROUND: This study aims to assess the impact of sotatercept on exercise tolerance, exercise capacity, and right ventricular function in pulmonary arterial hypertension. METHODS: SPECTRA (Sotatercept Phase 2 Exploratory Clinical Trial in PAH) was a phase 2a, single-arm, open-label, multicenter exploratory study that evaluated the effects of sotatercept by invasive cardiopulmonary exercise testing in participants with pulmonary arterial hypertension and World Health Organization functional class III on combination background therapy. The primary end point was the change in peak oxygen uptake from baseline to week 24. Cardiac magnetic resonance imaging was performed to assess right ventricular function. RESULTS: Among the 21 participants completing 24 weeks of treatment, there was a significant improvement from baseline in peak oxygen uptake, with a mean change of 102.74 mL/min ([95% CIs, 27.72–177.76]; P =0.0097). Sotatercept demonstrated improvements in secondary end points, including resting and peak exercise hemodynamics, and 6-minute walk distance versus baseline measures. Cardiac magnetic resonance imaging showed improvements from baseline at week 24 in right ventricular function. CONCLUSIONS: The clinical efficacy and safety of sotatercept demonstrated in the SPECTRA study emphasize the potential of this therapy as a new treatment option for patients with pulmonary arterial hypertension. Improvements in right ventricular structure and function underscore the potential for sotatercept as a disease-modifying agent with reverse-remodeling capabilities. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03738150.

24 August 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
RVRebecca R. Vanderpool
Rebecca R. Vanderpool
ADAnkit A. Desai
Ankit A. Desai
SKShannon M. Knapp
Shannon M. Knapp
MSMarc A. Simon
Marc A. Simon
AAAiden Abidov
Aiden Abidov
FRFranz P. Rischard
Franz P. Rischard
Prostacyclin reduces right ventricular contractility, but improves ejection fraction and exercise capacity in PAH http://ow.ly/m5S830dpcZv

1 April 2022 in Chest
Verified
Journal Article
Closed access
RVRebecca R. Vanderpool
Rebecca R. Vanderpool
KHKendall S. Hunter
Kendall S. Hunter
MIMichael Insel
Michael Insel
JGJoe G.N. Garcia
Joe G.N. Garcia
EBEdward J. Bedrick
Edward J. Bedrick
FRFranz P. Rischard
Franz P. Rischard

12 May 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
David HarrisDavid Harris
David Harris
MBMichael Badowski
Michael Badowski
BJBrandon Jernigan
Brandon Jernigan
RSRyan Sprissler
Ryan Sprissler
TETaylor Edwards
Taylor Edwards
MDMichael D. Dake
Michael D. Dake
SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.

1 October 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
MMMonica Mukherjee
Monica Mukherjee
SMStephen C. Mathai
Stephen C. Mathai
CJChristine Jellis
Christine Jellis
BFBenjamin H. Freed
Benjamin H. Freed
LYLisa R. Yanek
Lisa R. Yanek
TGthe PVDOMICS Study Group
the PVDOMICS Study Group
BACKGROUND: Defining qualitative grades of echocardiographic metrics of right heart chamber size and function is critical for screening, clinical assessment, and measurement of therapeutic response in individuals with pulmonary vascular disease (PVD). In a population enriched for PVD, we sought to establish qualitative grades and prognostic value of right heart chamber size and function. METHODS: We investigated 1053 study participants in PVDOMICS (Redefining Pulmonary Hypertension Through the PVD Phenomics Program) to determine clinical and echocardiographic differences associated with increasing pulmonary vascular resistance severity. Right heart chamber size and function were qualitatively assessed using a percentile-based approach above the median values to create a clinical grading system for right heart adaptation. The relationship between echocardiographic categories and all-cause mortality was examined using survival analyses adjusted for potential confounders. RESULTS: A stepwise increase in adverse right heart remodeling was observed with a concomitant decrease in functional parameters by pulmonary vascular resistance strata ( P <0.001 for all). Mild, moderate, and severe categories of right heart chamber size and dysfunction were defined using a percentile-based approach across the spectrum of PVD. During a median follow-up of 2.07 years (interquartile range, 1.23–3.01 years), 130 participants died (11.4%). Progressive pulmonary vascular resistance increase and 2DE evidence of right heart dysfunction inclusive of fractional area change, and right ventricular global longitudinal strain were independently associated with increased all-cause mortality risk in multivariate analysis adjusted for age, disease duration, and male sex. CONCLUSIONS: In this well-characterized sample of adults with diverse etiologies and varying PVD severity, we define categories of abnormal right heart chamber size and function. Further, we demonstrate a stepwise relationship between these categories of abnormal morphology and function and all-cause mortality. Defining grades of right ventricular dysfunction in individuals with known PVD has important clinical implications for monitoring disease progression and response to therapies.